torsemide has been researched along with enalapril in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 4 (57.14) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Campillo, NE; Guerra, A; Páez, JA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Beck, FX; Müller, E; Ohno, A; Pfaller, W; Seppi, T | 1 |
| Adams, RC; Furness, MS; Gill, DS; Holcombe, FO; Raw, AS; Yu, LX | 1 |
| Klues, HG; Martin, N; Ott, R | 1 |
2 review(s) available for torsemide and enalapril
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs).
Topics: Biological Availability; Carbamazepine; Cefuroxime; Chemistry Techniques, Analytical; Crystallography; Decision Trees; Drug Approval; Drug Stability; Drugs, Generic; Enalapril; Humans; Molecular Conformation; Phase Transition; Prazosin; Quality Control; Ranitidine; Solubility; Sulfonamides; Technology, Pharmaceutical; Therapeutic Equivalency; Torsemide; United States; United States Food and Drug Administration; Warfarin | 2004 |
5 other study(ies) available for torsemide and enalapril
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Neural computational prediction of oral drug absorption based on CODES 2D descriptors.
Topics: Administration, Oral; Humans; Models, Chemical; Neural Networks, Computer; Permeability; Quantitative Structure-Activity Relationship; Technology, Pharmaceutical | 2010 |
Inhibition of angiotensin-converting enzyme modulates structural and functional adaptation to loop diuretic-induced diuresis.
Topics: Aldosterone; Anesthesia; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Body Weight; Consciousness; Diuresis; Diuretics; Electrolytes; Enalapril; Hematocrit; Kidney Cortex; Kidney Function Tests; Kidney Tubules; Male; Rats; Rats, Wistar; Rubidium; Sodium; Sodium-Potassium-Exchanging ATPase; Sulfonamides; Torsemide; Urine; Vasoconstrictor Agents; Water-Electrolyte Balance | 1997 |
[Idiopathic hypereosinophilia with cardiac involvement].
Topics: Adult; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Cardiomyopathy, Restrictive; Cardiotonic Agents; Diagnosis, Differential; Digoxin; Diuretics; Drug Therapy, Combination; Echocardiography, Doppler; Enalapril; Endomyocardial Fibrosis; Female; Humans; Hypereosinophilic Syndrome; Magnetic Resonance Imaging; Mineralocorticoid Receptor Antagonists; Mitral Valve Insufficiency; Patient Compliance; Prognosis; Spironolactone; Sulfonamides; Torsemide | 2004 |